Drugs / TAS-116
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05655598 | Sep 2023 → Aug 2024 | endometrial cancer, female breast carcinoma, refractory malignant neoplasm, small cell lung carcinoma +2 | Brown University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05245968 | Dec 2021 → Dec 2026 expected | gastrointestinal stromal tumor | Taiho Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02965885 | Jul 2017 → May 2019 | cancer | Taiho Oncology, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04999761 Background | Jun 2021 → May 2026 overdue | alveolar soft part sarcoma, biliary tract cancer, colorectal cancer, esophageal cancer +4 | Taiho Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS-116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05655598 ↗ |
| Known as | Pimitespib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05245968 ↗ |
| Action | Inhibit | “heat shock protein 90 (HSP90) inhibitor” NCT02965885 ↗ |
| Modality | Small molecule | — CHEMBL3661115 ↗ |
| Route | Oral | “TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor” NCT02965885 ↗ |